NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis → Big Tech is spending billions each month on Nvidia’s AI superproject (From Weiss Ratings) (Ad) Free QNCX Stock Alerts $0.72 -0.07 (-8.92%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$0.71▼$0.7850-Day Range$0.76▼$1.1152-Week Range$0.71▼$1.70Volume444,216 shsAverage Volume90,619 shsMarket Capitalization$30.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Quince Therapeutics alerts: Email Address Ad Crypto 101 MediaMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look: Claim your free seat by clicking here now. About Quince Therapeutics Stock (NASDAQ:QNCX)Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Read More QNCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNCX Stock News HeadlinesJune 11 at 2:16 AM | americanbankingnews.comFinancial Comparison: Quince Therapeutics (NASDAQ:QNCX) & Ikena Oncology (NASDAQ:IKNA)June 4, 2024 | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Trading 5.7% Higher June 3, 2024 | businesswire.comQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemMay 13, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024May 13, 2024 | businesswire.comQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | businesswire.comQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceApril 25, 2024 | finance.yahoo.comQuince Therapeutics, Inc. (QNCX)April 2, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023April 1, 2024 | finance.yahoo.comQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsFebruary 22, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | businesswire.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 15, 2024 | finance.yahoo.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | businesswire.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsJanuary 4, 2024 | finance.yahoo.comQuince Therapeutics to Participate at Investor Events in January 2024November 11, 2023 | morningstar.comQuince Therapeutics Inc QNCXOctober 27, 2023 | benzinga.comChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 SharesOctober 25, 2023 | benzinga.comQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock OptionsOctober 23, 2023 | finance.yahoo.comQuince Therapeutics Completes Acquisition of EryDel S.p.A.September 28, 2023 | msn.comFDA lifts partial clinical hold on EryDel lead product EryDexSeptember 28, 2023 | finance.yahoo.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 7, 2023 | benzinga.comQuince Therapeutics President Awarded $692K Worth of Stock OptionsSeptember 6, 2023 | bizjournals.comDaily Digest: Currys aim to raise $50M for Oakland schools; Sotheby's opens new officeSeptember 6, 2023 | finance.yahoo.comQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentAugust 18, 2023 | benzinga.com325K Reasons To Be Bullish On Quince Therapeutics StockAugust 14, 2023 | benzinga.comQuince Therapeutics And 2 Other Stocks Under $3 Insiders Are BuyingSee More Headlines Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/12/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:QNCX CUSIPN/A CIK1662774 Webwww.quincetx.com Phone(650) 910-5717FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.72% Return on Assets-24.12% Debt Debt-to-Equity Ratio0.18 Current Ratio7.16 Quick Ratio7.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.98 per share Price / Book0.36Miscellaneous Outstanding Shares43,220,000Free Float35,955,000Market Cap$30.90 million OptionableOptionable Beta1.17 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Dirk Thye M.D. (Age 54)CEO, Chief Medical Officer & Director Comp: $856.5kDr. Charles S. Ryan J.D. (Age 60)Ph.D., President Comp: $524.47kMr. Brendan Hannah M.B.A. (Age 38)Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer Comp: $607.5kDr. Guenter R. Janhofer M.D.Ph.D., Chief Scientific OfficerMs. Stacy RoughanVice President of Corporate Communications & Investor RelationsMs. Mary Ellen SillivosVice President of Human ResourcesDr. Stewart A. Low Ph.D.Head of DiscoveryMore ExecutivesKey CompetitorsVerastemNASDAQ:VSTMVistagen TherapeuticsNASDAQ:VTGNVaxartNASDAQ:VXRTCardiff OncologyNASDAQ:CRDFaTyr PharmaNASDAQ:LIFEView All CompetitorsInsidersDavid LamondBought 22,627 shares on 12/14/2023Total: $23,532.08 ($1.04/share)David LamondBought 22,327 shares on 12/12/2023Total: $22,773.54 ($1.02/share)David LamondBought 19,123 shares on 12/7/2023Total: $19,314.23 ($1.01/share)David LamondBought 19,123 shares on 12/5/2023Total: $19,314.23 ($1.01/share)David LamondBought 14,378 shares on 12/1/2023Total: $13,515.32 ($0.94/share)View All Insider Transactions QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed in 2024? Quince Therapeutics' stock was trading at $1.05 at the start of the year. Since then, QNCX shares have decreased by 31.9% and is now trading at $0.7150. View the best growth stocks for 2024 here. When is Quince Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our QNCX earnings forecast. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.26) earnings per share for the quarter. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QNCX) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredPotentially Pocket $767/Day with AIWhat if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.